EDN1 and metastatic prostate carcinoma: Moreover, comparing with the normal control samples, EDN1 mRNA expression was increased in inflammatory breast cancer, nasopharyngeal carcinoma, metastatic prostate cancer, gastric cancer, papillary thyroid cancer, and ovarian cancer epithelial cells (Fig. 5B).